15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 7 firms covering Humacyte Inc, 6 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $1.25 to $25.00 (about 20.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $6.85 sits 986% above the current $0.63. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.08 next quarter toward $-0.24 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 ratings
Moderate Buy
Strong Buy00%
Buy686%
Hold114%
Sell00%
Strong Sell00%
Based on 7 analysts giving stock ratings to Humacyte Inc.
As of Jul, 6 of 7 firms rate HUMA a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
HUMA EPS & revenue forecast
EPS · NEXT QUARTER
$-0.08
Range $-0.10 – $-0.06 · 3 analysts · -24% YoY
Next period, 3 analysts expect Humacyte Inc to earn $-0.08 a share (range $-0.10 – $-0.06), versus $-0.11 a year earlier. Full-year consensus is $-0.35, growing to $-0.24 the year after.
REVENUE · NEXT QUARTER
$2.2M
Range $1.4M – $3.0M · 3 analysts · +189% YoY
Revenue is expected to reach $2.2M (range $1.4M – $3.0M), +189.0% year-over-year. Full-year consensus is $6.3M, rising to $26.3M next year.
Top analysts covering Humacyte Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on HUMA.
#1
Swayampakula Ramakanth
HC Wainwright & Co. · Rank #230
Buy
$4.00+534.4% to target
Overall win rate
37%
+ Follow
#2
Bruce Jackson
Benchmark · Rank #317
Buy
$2.00+217.2% to target
Overall win rate
35%
+ Follow
#3
Jason Kolbert
D. Boral Capital · Rank #346
Buy
$25.00+3865.1% to target
Overall win rate
22%
+ Follow
#4
Ryan Zimmerman
BTIG
Buy
$2.00+217.2% to target
Coverage
—
+ Follow
#5
JJ
Joshua Jennings
TD Cowen
Buy
$1.25+98.3% to target
Coverage
—
+ Follow
HUMA stock forecast FAQ
What is HUMA's average 12-month price target?+
The 5 analysts with a live target average $6.85 for Humacyte Inc over the next 12 months, ranging from a $25.00 high to a $1.25 low.
Is HUMA stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 7 analyst ratings, 6 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for HUMA?+
The Street-high target is $25.00 (D. Boral Capital), and the Street-low is $1.25 (TD Cowen). The average of all 5 active targets is $6.85.
How many Wall Street analysts cover HUMA?+
7 analysts have an active rating on Humacyte Inc, and 5 firms carry a live 12-month price target.
Who is the most accurate analyst covering HUMA?+
Among analysts who currently cover HUMA, Swayampakula Ramakanth of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #230). Their current call is Buy with a $4.00 target.
What is Humacyte Inc's projected EPS for next quarter?+
The consensus estimate is $-0.08 per share (range $-0.10 – $-0.06) across 3 analysts. Full-year EPS is projected at $-0.35, rising to $-0.24 the following year.
How much revenue is Humacyte Inc expected to report next quarter?+
Consensus revenue is $2.2M (range $1.4M – $3.0M). Full-year revenue is projected at $6.3M, growing to $26.3M next year.
Have analysts been upgrading or downgrading HUMA lately?+
As of Jul, 6 of 7 firms rate HUMA a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their HUMA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
